Roivant Sciences

Close-up of human eye

Biotech

Immunovant pays out $39M to call time on 1st-gen FcRn inhibitor

Immunovant has confirmed that its first-generation FcRn inhibitor has been scrapped a month after the asset flunked phase 3 eye disease trials.

James Waldron May 20, 2026 8:31am

An artists concept of gene editing A DNA strand appears in blue with edited regions in red

Editas prioritizes in vivo therapies, seeks reni-cel partner

Oct 22, 2024 9:39am

Sketch of lungs

Roivant unveils new ‘vant’ to advance Bayer hypertension med

Sep 10, 2024 7:57am

Photo of a final puzzle piece about to fit into a puzzle

Top 10 smartest deals in biopharma

Jun 24, 2024 6:00am

artificial intelligence chip

Lokavant launches AI solution for real-time trial optimization

Jun 11, 2024 3:45pm

bet poker chips

Roivant's Hemavant bet winds down after cutting ex-Eisai drug

Feb 13, 2024 2:01pm